Abstract
Résumé
- Fuster V.
- Rydén L.E.
- Cannom D.S.
- et al.
Quality | Comments |
---|---|
High | Future research unlikely to change confidence in estimate of effect; eg, multiple well-designed, well-conducted clinical trials |
Moderate | Further research likely to have an important impact on confidence in estimate of effect and may change the estimate; eg, limited clinical trials, inconsistency of results or study limitations |
Low | Further research very likely to have a significant impact on the estimate of effect and is likely to change the estimate; eg, small number of clinical studies or cohort observations |
Very low | The estimate of effect is very uncertain; eg, case studies, consensus opinion |
Factor | Comment |
---|---|
Quality of evidence | The higher the quality of evidence, the greater the probability that a strong recommendation is indicated; eg, strong recommendation that patients with AF at moderate to high risk of stroke be treated with oral anticoagulants. |
Difference between desirable and undesirable effects | The greater the difference between desirable and undesirable effects, the greater the probability that a strong recommendation is indicated; eg, strong recommendation that patients with AF ≥ 48-h duration receive oral anticoagulation therapy for at least 3 wk prior to planned cardioversion and 4 wk following. |
Values and preferences | The greater the variation or uncertainty in values and preferences, the higher the probability that a conditional recommendation is indicated; eg, aspirin may be a reasonable alternative to oral anticoagulant therapy in patients at low risk of stroke. |
Cost | The higher the cost, the lower the likelihood that a strong recommendation is indicated; eg, conditional recommendation for catheter ablation as first-line therapy for AF. |
- 1Etiology and Initial Investigations
- 2Management of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department
- 3Rate and Rhythm Management
- 4Catheter Ablation for Atrial Fibrillation/Atrial Flutter
- 5Surgical Therapy
- 6Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter
- 7Prevention and Treatment of Atrial Fibrillation Following Cardiac Surgery
Appendix 1. Primary and secondary panel members
Primary panel members | ||
---|---|---|
Anne M. Gillis, MD, FRCP(C) | Cochair | Dept of Cardiac Sciences, University of Calgary, Libin Cardiovascular Institute of Alberta |
Allan Skanes, MD, FRCP(C) | Cochair | Division of Cardiology, University of Western Ontario |
Stuart Connolly, MD, FRCP(C) | Member | Division of Cardiology, Department of Medicine, McMaster University |
John Cairns, MD, FRCP(C), | Member | Faculty of Medicine, University of British Columbia |
Jafna Cox, BA, MD, FRCP(C), FACC | Member | Division of Cardiology, Dalhousie University |
Paul Dorian, MD, MSc. FRCP(C) | Member | Division of Cardiology, University of Toronto |
Jeff Healey, MD, FRCP(C) | Member | Division of Cardiology, Medicine Department, McMaster University |
Laurent Macle, MD, FRCP(C) | Member | Electrophysiology Service, Montreal Heart Institute, Université de Montréal |
Sean McMurty, MD, PhD, FRCP(C) | Member | Division of Cardiology, University of Alberta |
Brent Mitchell, MD, FRCP(C) | Member | University of Calgary, Libin Cardiovascular Institute of Alberta |
Stanley Nattel, MD, FRCP(C) | Member | Montreal Heart Institute, Université de Montréal |
Pierre Page, MD, FRCPS | Member | Montreal Heart Institute, Université de Montréal |
Ratika Parkash, MD, MSc, FRCP(C) | Member | Division of Cardiology, Dalhousie University |
P. Timothy Pollak, MD, PhD FRCP(C) | Member | Department of Cardiac Sciences, and Physiology & Pharmacology, University of Calgary |
Michael Stephenson, MD, CCFP, FCFP | Member | Representative of The College of Family Physicians of Canada, Ancaster, Ontario |
Ian Stiell, MD, MSc, FRCP(C) | Member | Department of Emergency Medicine, Ottawa Hospital Research Institute, University of Ottawa |
Mario Talajic, MD, FRCP(C) | Member | Montreal Heart Institute, Université de Montréal |
Teresa Tsang, MD, FRCP(C) | Member | Division of Cardiology, University of British Columbia |
Atul Verma, MD, FRCP(C) | Member | Heart Rhythm Program, Southlake Regional Health Centre |
Jan Brozek, MD, PhD | Special Collaborator | Departments of Clinical Epidemiology & Biostatistics and Medicine. McMaster University |
Grant Stotts, MD, FRCP(C) | Special Collaborator | University of Ottawa, The Ottawa Hospital. Representative of the Canadian Stroke Network |
Secondary panel members | ||
Malcolm Arnold, MD, FRCP(C) | Member | Division of Cardiology, University of Western Ontario, |
David Bewick, MD, FRCP(C) | Member | St. John's, New Brunswick |
Vidal Essebag, MD, MSc, FRCP(C) | Member | Department of Cardiology, McGill University Health Center |
Milan Gupta, MD, FRCP(C) | Member | Division of Cardiology, Brampton Civic Hospital |
Brett Heilbron, MBChB, FRCP(C) | Member | St. Paul's Hospital Heart Centre, University of British Columbia |
Charles Kerr, MD, FRCP(C), | Member | St. Paul's Hospital Heart Centre, University of British Columbia |
Bob Kiaii, MD, FRCS(C) | Member | Division of Cardiac Surgery, University of Western Ontario |
Jan Surkes, BA (hon) MD FRCP(C) | Member | Department of Medicine, Langley Memorial Hospital, Langley, BC |
George Wyse, MD, PhD, FRCP(C) | Member | Department of Cardiac Sciences, University of Calgary, Libin Cardiovascular Institute of Alberta |
References
- Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.Circulation. 2004; 110: 1042-1046
- Canadian Cardiovascular Society Consensus Conference: Atrial fibrillation 2004 executive summary.http://www.ccs.ca/download/consensus_conference/consensus_conference_archives/2004_Atrial_Fib_ES.pdf(Accessed November 11, 2010)
- Rhythm control versus rate control for atrial fibrillation and heart failure.N Engl J Med. 2008; 358: 2667-2677
- Lenient versus strict rate control in patients with atrial fibrillation.N Engl J Med. 2010; 362: 1363-1373
- Effect of dronedarone on cardiovascular events in atrial fibrillation.N Engl J Med. 2009; 360: 668-678
- Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009; 361: 1139-1151
- Effect of clopidogrel added to aspirin in patients with atrial fibrillation.N Engl J Med. 2009; 360: 2066-2078
- A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation.J Cardiovasc Electrophysiol. 2009; 20: 138-144
- Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.Circ Arrhythm Electrophysiol. 2010; 3: 32-38
- Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.JAMA. 2010; 303: 333-340
- Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale.Circ Arrhythm Electrophysiol. 2009; 2: 218-224
- Renovating CCS guidelines and position statements: a new foundation.Can J Cardiol. 2010; 26: 233-235
- CCS guidelines and position statements are important, but do they make the GRADE?.Can J Cardiol. 2010; 26: 177-178
- Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project.Qual Saf Health Care. 2003; 12: 18-23
- ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Circulation. 2006; 114: e257-e354
- Why guideline-making requires reform.JAMA. 2009; 301: 429-431
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.BMJ. 2008; 336: 924-926
- Rating quality of evidence and strength of recommendations: what is “quality of evidence” and why is it important to clinicians?.BMJ. 2008; 336: 995-998
- Grading quality of evidence and strength of recommendations for diagnostic tests and strategies.BMJ. 2008; 336: 1106-1110
- Rating quality of evidence and strength of recommendations: incorporating considerations of resources use into grading recommendations.BMJ. 2008; 336: 1170-1173
- Rating quality of evidence and strength of recommendations: going from evidence to recommendations.BMJ. 2008; 336: 1049-1051
Article Info
Publication History
Footnotes
The disclosure information of the authors and reviewers are available from the CCS on the following Web sites: www.ccs.ca and www.ccsguidelineprograms.ca.
This statement was developed following a thorough consideration of medical literature and the best available evidence and clinical experience. It represents the consensus of a Canadian panel comprised of multidisciplinary experts on this topic with a mandate to formulate disease-specific recommendations. These recommendations are aimed to provide a reasonable and practical approach to care for specialists and allied health professionals obliged with the duty of bestowing optimal care to patients and families, and can be subject to change as scientific knowledge and technology advance and as practice patterns evolve. The statement is not intended to be a substitute for physicians using their individual judgment in managing clinical care in consultation with the patient, with appropriate regard to all the individual circumstances of the patient, diagnostic and treatment options available and available resources. Adherence to these recommendations will not necessarily produce successful outcomes in every case.
A complete list of the Primary and Secondary Panel Members are listed in the Appendix on page 30.